Search results for "Prognosis."

showing 10 items of 2044 documents

Prognostic factors for non-asphyxia-related cardiac arrest patients undergoing extracorporeal rewarming - HELP Registry Study

2020

Objective: Extracorporeal rewarming is the treatment of choice for patients who had hypothermic cardiac arrest, allowing for best neurologic outcome. The authors’ goal was to identify factors associated with survival in nonasphyxia-related hypothermic cardiac arrest patients undergoing extracorporeal rewarming. Design: All 38 cardiac surgery departments in Poland were encouraged to report consecutive hypothermic cardiac arrest patients treated with extracorporeal life support. All variables collected were analyzed in order to compare survivor and nonsurvivor groups. The parameters available at the initiation of extracorporeal rewarming were considered as potential predictors of survival in …

extracorporeal circulationmedicine.medical_specialtycardiac arrestHypothermia030204 cardiovascular system & hematologyhyperlactatemiaExtracorporeallaw.invention03 medical and health sciences0302 clinical medicine030202 anesthesiologylawHumansMedicineRegistriesRewarmingSurvival rateRetrospective StudiesUnivariate analysisbusiness.industryExtracorporeal circulationRetrospective cohort studyout-of-hospitalPrognosisIntensive care unitCardiopulmonary ResuscitationHeart ArrestCardiac surgeryAnesthesiology and Pain MedicineLife supportAnesthesiaPolandCardiology and Cardiovascular Medicinebusiness
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tu…

2009

Metallothionein is a group of small molecular weight cysteine-rich proteins with a broad variety of functions. Metallothionein has been shown to regulate apoptosis and proliferation. Overexpression of metallothionein frequently occurs in human tumors and is related to prognosis as well as therapy response. However, metallothionein expression and its clinical relevance in cholangiocarcinoma have not been investigated. The present study aimed to analyze metallothionein over-expression and its possible prognostic impact in intrahepatic cholangiocarcinoma and hilar extrahepatic cholangiocarcinoma (Klatskin tumors). We investigated the relationship of immunohistochemically demonstrated metalloth…

inorganic chemicalsMalePathologymedicine.medical_specialtyMedizinApoptosisHepatic Duct CommonBile Duct NeoplasmKaplan-Meier EstimateBiologydigestive systemPathology and Forensic MedicineBile duct cancerCholangiocarcinomamedicineBiomarkers TumorIn Situ Nick-End LabelingMetallothioneinHumansIntrahepatic CholangiocarcinomaNeoplasm Stagingurogenital systemBile ductCancerKlatskin's tumorMiddle Agedmedicine.diseasePrognosisImmunohistochemistrydigestive system diseasesUp-Regulationmedicine.anatomical_structureBile Ducts IntrahepaticKi-67 AntigenBile Duct NeoplasmsImmunohistochemistryFemaleMetallothioneinKlatskin Tumor
researchProduct

Cardiorenal Syndrome: New Pathways and Novel Biomarkers

2021

Cardiorenal syndrome (CRS) is a multi-organ disease characterized by the complex interaction between heart and kidney during acute or chronic injury. The pathogenesis of CRS involves metabolic, hemodynamic, neurohormonal, and inflammatory mechanisms, and atherosclerotic degeneration. In the process of better understanding the bi-directional pathophysiological aspects of CRS, the need to find precise and easy-to-use markers has also evolved. Based on the new pathophysiological standpoints and an overall vision of the CRS, the literature on renal, cardiac, metabolic, oxidative, and vascular circulating biomarkers was evaluated. Though the effectiveness of different extensively applied biomark…

kidneyrenal injuryDiseaseCardiorenal syndromeReviewheartBioinformaticsBiochemistryMicrobiologyPathogenesisRenal injuryotorhinolaryngologic diseasesMedicineHumansNGALKIM-1Molecular Biologycardiorenal syndromeKidneymicroRNACardio-Renal Syndromebusiness.industryAcute kidney injuryChronic injurymedicine.diseasechronic renocardiac syndromenovel biomarkersPrognosisQR1-502proBNPCirculating biomarkersmedicine.anatomical_structureacute kidney injurybusinessAcute kidney injury; Cardiorenal syndrome; Chronic renocardiac syndrome; Heart; Kidney; KIM-1; MicroRNA; NGAL; Novel biomarkers; ProBNP; Renal injuryBiomarkersBiomolecules
researchProduct

Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic rev…

2019

Background Our objectives were to critically appraise and summarise the current evidence for the effectiveness of using cardiovascular disease (CVD) risk scoring (total risk assessment - TRA) in routine risk assessment in primary prevention of CVD compared with standard care with regards to patients outcomes, clinical risk factor levels, medication prescribing, and adverse effects. Methods We carried out an overview of existing systematic reviews (SRs). Presentation of the results aligned guidelines from the PRISMA statement. The data is presented as a narrative synthesis. We searched MEDLINE (Ovid), EMBASE, CENTRAL and SCOPUS databases from January 1990 to March 2017, reviewed the referenc…

lcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyMEDLINEDisease030204 cardiovascular system & hematologyDecision Support Techniques03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicPredictive Value of TestsmedicineHumans030212 general & internal medicineAdverse effectAngiologyRisk assessmentPrimary preventionbusiness.industryPrognosisCardiovascular systemSystematic reviewBlood pressureCardiovascular diseasesRisk factorslcsh:RC666-701Emergency medicineObservational studyCardiology and Cardiovascular MedicineRisk assessmentbusinessSystematic Reviews as TopicResearch ArticleBMC Cardiovascular Disorders
researchProduct

Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas

2019

C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immu…

lcsh:Immunologic diseases. Allergy0301 basic medicinetumorLung NeoplasmsMicroenvironmentPrognosiImmunologyComplementBreast Neoplasmschemical and pharmacologic phenomenaKaplan-Meier EstimateBiology03 medical and health sciencesClassical complement pathway0302 clinical medicineImmune systemimmune system diseasesmedicineHumansImmunology and Allergycomplementclassical pathwayskin and connective tissue diseasesC1qOriginal ResearchTumorInnate immune systemEffectorComplement C1qComputational BiologyCancerPrognosismedicine.diseasemicroenvironmentKidney NeoplasmsComplement systemClear cell renal cell carcinomaC1q; Classical pathway; Complement; Microenvironment; Prognosis; Tumor030104 developmental biologyClassical pathwayCancer researchAdenocarcinomaprognosislcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia

2021

Simple Summary Although the prognosis of acute lymphoblastic leukemia (ALL) has improved significantly during the past decades, ALL remains a major cause of pediatric cancer mortality, and more accurate risk-stratification is required. We investigated IGF2BP3, which has previously been associated with aggressive cancers, and found high and subtype-specific expression of IGF2BP3 in B-cell ALL, that was associated with good outcome in high-risk patients. Results suggest that IGF2BP3 could be useful to improve stratification and prognosis of B-ALL. Abstract The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved i…

lähetti-RNAmRNAproliferation3122 Cancersleukemiabiomarkkeritennusteetlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)lcsh:RC254-282Articleinsulin-like growth factor 2 mRNA-binding protein 3 (<i>IGF2BP3</i>)akuutti lymfaattinen leukemiapediatric B-cell acute lymphoblastic leukemia1182 Biochemistry cell and molecular biologysyöpätauditproteiinitprognosisproteinCancers
researchProduct

Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer

2019

There is still a great unmet medical need concerning diagnosis and treatment of breast cancer which could be addressed by utilizing specific molecular targets. Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy. Utilizing an anti-tumor vaccine based on a synthetically prepared glycopeptide, we generated a monoclonal antibody (mAb) GGSK-1/30, selectively recognizing human tumor-associated MUC1. This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on health…

medicine.drug_classEstrogen receptorMUC1Breast NeoplasmsMice TransgenicDeferoxamineMonoclonal antibody89Zr03 medical and health sciences0302 clinical medicineBreast cancerIn vivoCell Line TumorBiomarkers TumormedicineAnimalsHumansTissue Distributionskin and connective tissue diseasesMUC1Triple-negative breast cancermAbRadioisotopesMice Inbred BALB Cbiologybusiness.industryMucin-1breast cancer diagnosisAntibodies MonoclonalCancerGeneral MedicinePrognosismedicine.diseaseImmunohistochemistryMice Inbred C57BLPositron-Emission Tomographybiology.proteinCancer researchFemale030211 gastroenterology & hepatologyZirconiumAntibodybusinessResearch PaperInternational Journal of Medical Sciences
researchProduct

Multimodality imaging strategies for the assessment of aortic stenosis: Viewpoint of the heart valve clinic international database (HAVEC) group

2016

International audience; Aortic stenosis is the most frequent valvular heart disease. In aortic stenosis, therapeutic decision essentially depends on symptomatic status, stenosis severity, and status of left ventricular systolic function. Surgical aortic valve replacement or transcatheter aortic valve implantation is the sole effective therapy in symptomatic patients with severe aortic stenosis, whereas the management of asymptomatic patients remains controversial and is mainly based on individual risk stratification. Imaging is fundamental for the initial diagnostic work-up, follow-up, and selection of the optimal timing and type of intervention. The present review provides specific recomme…

medicine.medical_specialty030204 cardiovascular system & hematologyDoppler echocardiographyAsymptomaticMultimodal ImagingRisk Assessment03 medical and health sciences0302 clinical medicineAortic valve replacementInternal medicinemedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineHeart valvehumanaortic valve stenosis ◼ biomarkers ◼ echocardiography Doppler ◼ guideline ◼ prognosis ◼ standardsalgorithmmedicine.diagnostic_testbusiness.industrypractice guidelinevalvular heart diseaseAortic Valve Stenosismedicine.diseasebiological markerPrognosis3. Good healthStenosismedicine.anatomical_structureclassificationAortic valve stenosisPractice Guidelines as TopicCardiologycardiovascular system[SDV.IB]Life Sciences [q-bio]/BioengineeringRadiologymedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentbusinessAlgorithmsBiomarkers
researchProduct

Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Pneumonia ViralMEDLINEBetacoronavirusRisk FactorsInternal medicinePandemicAtrial FibrillationmedicineHumansRisk factorPandemicsbiologybusiness.industrySARS-CoV-2Discussion ForumCOVID-19Atrial fibrillationmedicine.diseasebiology.organism_classificationPrognosisItalyCardiovascular DiseasesCardiology and Cardiovascular MedicinebusinessCoronavirus InfectionsCoronavirus InfectionsBetacoronavirusEuropean heart journal
researchProduct